top of page

WHO issues rapid communication on updated guidance for the treatment of drug-resistant tuberculosis

A rapid communication released by the World Health Organization (WHO) Global Tuberculosis Programme has announced upcoming updates to the guidance on the treatment of drug-resistant tuberculosis (DR-TB). These updates include shorter novel 6-month all-oral regimens for the treatment of multidrug- and rifampicin-resistant TB (MDR/RR-TB), with or without additional resistance to fluoroquinolones (pre-XDR-TB) as well as an alternative 9-month all-oral regimen for the treatment of MDR/RR-TB. Read Here.

28 views0 comments

Recent Posts

See All

Treat Action Group 2023 Pipeline Report

Their annual review provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB). View the full

Comments


bottom of page